Related Experiment Video
Updated: Dec 26, 2025

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
Published on: January 7, 2019
A bioengineered arginine-depleting enzyme as a long-lasting therapeutic agent against cancer
Sai-Fung Chung1, Chi-Fai Kim1, Suet-Ying Tam1
1Department of Applied Biology and Chemical Technology, Lo Ka Chung Research Centre for Natural Anti-Cancer Drug Development and State Key Laboratory of Chemical Biology and Drug Discovery, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China.
Abstract:
L-Arginine (L-Arg) depletion has attracted great attention in cancer therapy. Although two types of arginine-depleting enzymes, arginine deiminase (ADI) and human arginase I, are undergoing clinical trials, random site of PEGylation, low efficacy of heavy metal as co-factor, and immunogenicity limit the performance of these drugs and cause difficulty in a homogeneous production. Here we screened ten catalytic metal ions and have successfully produced a site-specific mono-PEGylated human arginase I mutant by conjugating the Cys45 residue to PEG-maleimide to minimize the decrease in activity and produce a homogeneous product. The catalytic efficiency trend of metal ion-enriched human arginase I mutant (HAI) was Co2+ > Ni2+ ≫ Mn2+. The overall kcat/KM values of Co-HAI and Ni-HAI were higher than Mn-HAI by ~ 8.7- and ~ 5.2-folds, respectively. Moreover, the results of enzyme kinetics and circular dichroism spectrometry demonstrated that the 20 or 40 kDa linear and branched PEG attached on the HAI surface did not affect the enzyme activity and the protein secondary structures. In vitro studies showed that both Co-HAI-PEG20L and Ni-HAI-PEG20L inhibited the growth of eight types of cancer cell lines. The pharmacodynamic study in mice demonstrated that the i.p. administration of Co-HAI-PEG20L at 13 mg/kg and Ni-HAI-PEG20L at 15 mg/kg was able to maintain a L-Arg level below its detection limit for over 120 h after one injection. The body weights of mice could return to normal levels within 5 days after injection, showing that the doses were well-tolerated. Therefore, both the Ni-HAI-PEG20L and Co-HAI-PEG20L are promising candidates for cancer therapy. KEY POINTS: • Mono-PEGylation applied on human arginase I mutant (HAI) successfully. • The catalytic efficiency of Co- and Ni-enriched HAI was higher than the wild type. • At least eight types of cancer cell lines were inhibited by Co- and Ni-HAI-PEG20L. • Co- and Ni-HAI-PEG20L were able to achieve weekly depletion of L-Arg. Graphical abstract.
Insights
This study developed a site-specific mono-PEGylated human arginase I mutant for cancer therapy. The enhanced enzyme, enriched with cobalt or nickel, effectively depletes L-arginine and inhibits multiple cancer cell lines.
Area of Science:
- Biochemistry
- Biotechnology
- Oncology
Background:
- L-arginine (L-Arg) depletion is a promising cancer therapy strategy.
- Existing arginine-depleting enzymes face challenges like random PEGylation, low efficacy, and immunogenicity.
Purpose of the Study:
- To develop a homogeneous and highly active PEGylated human arginase I mutant for enhanced cancer therapy.
- To evaluate the catalytic efficiency, activity, and in vitro/in vivo efficacy of the modified enzyme.
Main Methods:
- Screening of ten catalytic metal ions for human arginase I mutant (HAI) enrichment.
- Site-specific mono-PEGylation of HAI at Cys45 using PEG-maleimide.
- Enzyme kinetics, circular dichroism, in vitro cancer cell growth inhibition assays, and in vivo pharmacodynamic studies in mice.
Main Results:
- Site-specific mono-PEGylation of HAI was successfully achieved without compromising enzyme activity or structure.
- Cobalt (Co)- and Nickel (Ni)-enriched HAI exhibited significantly higher catalytic efficiency compared to Manganese (Mn)-enriched HAI.
- Co- and Ni-HAI-PEG20L demonstrated potent inhibition against eight cancer cell lines and maintained L-Arg depletion for over 120 hours in mice.
Conclusions:
- Site-specific mono-PEGylated human arginase I mutants enriched with Co or Ni are effective L-arginine depleting agents.
- These modified enzymes show significant promise as well-tolerated and homogeneous therapeutic candidates for cancer treatment.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle

